A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

NCT00389324 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunologic Deficiency Syndrome

Interventions

BIOLOGICAL: Immune Globulin Intravenous (Human)

Sponsor

Grifols Therapeutics LLC